Mazdutide vs Retatrutide
How Mazdutide and Retatrutide compare on research category, evidence tier, regulatory status, and reported side effects.
The verdict
Both are next-generation metabolic peptides, but they are not the same bet. Mazdutide is a GLP-1 plus glucagon dual agonist with obesity approval in China, while Retatrutide adds GIP as a third receptor and has posted the bigger trial weight-loss headlines. Mazdutide has the cleaner current approval story in its market; Retatrutide is the more powerful-looking investigational compound if the Phase 3 data holds.
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist, same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Mazdutide if users wanting a glp/glucagon agonist with cleaner side effect profile than survodutide reports or followers of chinese metabolic-drug development.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Mazdutide and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Common questions
- Can you stack Mazdutide with Retatrutide?
- Neither entry lists the other as a stack partner. Each full entry has its own stacking notes.
- What's the dose difference between Mazdutide and Retatrutide?
- Mazdutide: Start 3 mg weekly. Titrate to 6-9 mg over 4-week steps based on tolerance.
- Retatrutide: Start 2mg sub-q weekly. Titrate by 2mg every 4 weeks based on tolerance. Trials went up to 12mg; most users plateau benefit at 8-12mg.
- Is Mazdutide or Retatrutide FDA approved?
- Mazdutide: Not FDA approved. Approved in China (2025, Innovent, brand Xinermei) for obesity and type 2 diabetes. Eli Lilly holds ex-China rights (LY-3305677) and runs US development (Phase 2).
- Retatrutide: Investigational. In Phase 3 trials with Eli Lilly. Not yet approved.
- What are the side effects of Mazdutide vs Retatrutide?
- Mazdutide: Nausea; Constipation or diarrhea; Mild fatigue.
- Retatrutide: Nausea (especially first 2 weeks of each titration step); Vomiting; Constipation or diarrhea.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.